Iron chelation therapy

Reviews in Clinical and Experimental Hematology

Volumn 4, Issue 4, 2000, Pages 337-361

  Hershko, Chaim ^a   Hoffbrand, A Victor ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIETHYL 3 HYDROXY 4 PYRIDONE; 4 [3,5 BIS(HYDROXYPHENYL) 1,2,4 TRIAZOL 1 YL]BENZOIC ACID; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; IRC 011; IRON CHELATING AGENT; N,N' BIS(2 HYDROXYBENZOYL)ETHYLENEDIAMINE N,N' DIACETIC ACID; PYRIDOXAL ISONICOTINOYLHYDRAZONE; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; ANEMIA; ARTHRITIS; ARTICLE; BLOOD TRANSFUSION; BONE MALFORMATION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDUCED DISEASE; HUMAN; IRON CHELATION; IRON OVERLOAD; LIVER DYSFUNCTION; MOUSE; NAUSEA; NONHUMAN; PERCEPTION DEAFNESS; RAT; SURVIVAL; THALASSEMIA; WELLBEING;

EID: 0034583962     PISSN: 11270020     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-0734.2000.00024.x     Document Type: Article

References (130)

1. From antibiotic to chelating agent
2. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients
3. A trial to investigate the relationship between DFO pharmacokinetics and metabolism and DFO-related toxicity
4. Results of long-term iron-chelating therapy
5. Iron chelating therapy and the treatment of thalassemia
6. A risk-benefit assessment of iron-chelation therapy
7. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload
8. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia
9. A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload
10. Continuous desferrioxamine infusion by an infusor in thalassaemia major
11. Desferrioxamine depot (CGH 749B): A new formulation allowing the prospect of a daily s.c. injection
12. A new depot formulation of desferrioxamine (ICL749B) given as subcutaneous bolus injection in transfusion dependent β-thalassemic patients: Update on the dosage-finding program
13. Magnetic susceptibility measurement of human iron stores
14. Quantification of liver iron concentration with magnetic resonance imaging by combining T1-, T2-weighted spin echo sequences and a gradient echo sequence
15. Iron deposition in the anterior pituitary in homozygous beta-thalassemia: MRI evaluation and correlation with gonadal function
16. The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation
17. Kinetics of removal and reappearance of non transferrin bound plasma ion with desferrioxamine therapy
18. Effect of ascorbic acid deficiency on serum ferritin concentration in patients with beta thalassemia
19. Survival in medically treated patients with homozygous β-thalassemia
20. The prognosis for adults with thalassaemia major
21. Hepatic iron concentrations combined with long term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major
22. High-dose desferrioxamine as a cause of growth failure in thalassemic patients
23. Deferoxamine-induced bone dysplasia in patients with thalassemia major
24. Growth failure and bony changes induced by deferoxamine
25. Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine
26. Long-term follow-up of skeletal dysplasia in thalassaemia major
27. Visual and auditory neurotoxicity in patients receiving sub-cutaneous deferoxamine infusions
28. Ocular changes in patients undergoing long-term desferrioxamine treatment
29. Acute changes in renal function associated with deferoxamine therapy
30. Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions
31. Desferrioxamine ototoxicity: Evaluation of risk factors in thalassaemic patients and guidelines for safe dosage
32. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration
33. Yersinia sepsis in patients with iron overload treated with deferoxamine
34. Clinical manifestations and therapy of transfusional haemosiderosis
35. Survival and disease complications in thalassemia major
36. Results of long-term subcutaneous desferrioxamine therapy
37. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major
38. Current therapy of Cooley's anemia. A decade of experience with subcutaneous desferrioxamine
39. Survival and morbidity in transfusion-dependent thalassemic patients on subcutaneous desferrioxamine chelation
40. Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassaemia major
41. Combined subcutaneous and high-dose intravenous deferoxamine therapy of thalassemia
42. Current treatment of Cooley's anemia. Intravenous chelation therapy
43. Pregnancy in patients with well-treated beta-thalassemia: Outcome for mothers and newborn infants
44. Deferoxamine treatment during pregnancy: Is it harmful?
45. The development of hydroxypyridin-4-ones as orally active iron chelators
46. Design, properties, and effective use of the oral chelator L1 and other ketohydroxypyridines in the treatment of transfusional iron overload in thalassemia
47. Oral iron chelation with deferiprone
48. Deferiprone. A review of its clinical potential in iron overload in β-thalassaemia major and other transfusion-dependent diseases
49. Long-term therapy with deferiprone
50. Oral iron-chelating therapy: The L1 experience
51. Evidence of toxicity due to 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in normal rats
52. Toxicological and metabolic studies with CGP 37 391 (L1)
53. Results of long-term deferiprone (L1) therapy: A report of the International Study Group on Oral Iron Chelators
54. The biochemical and pathological basis of zinc physiology
55. Toxicity of iron chelator L1
56. Development of iron chelator L1
57. The iron chelator L1 potentiates oxidative damage in iron-loaded liver cells
58. Potentiation of iron accumulation in cardiac myocytes during the treatment of iron overload in gerbils with the hydroxypyridone iron chelator CP94
59. Relative effectiveness of deferoxamine (DFO) and deferiprone (L1) in protecting iron-loaded gerbils from non-transferrin-bound iron (NTBI) toxicity
60. Cardioprotective effect of alpha-tocopherol, ascorbate, deferoxamine, and deferiprone: Mitochondrial function in cultured, iron-loaded heart cells
61. Liver iron depletion and toxicity of the iron chelator deferiprone (L1, CP20) in the guinea pig
62. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload
63. The pharmacokinetics and pharmacodynamics of the oral chelator deferiprone (L1) in relation to hemoglobin levels
64. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxy-pyrid-4-one in patients with thalassemia
65. Contrasting interspecies efficacy and toxicology of 1,2-diethyl-3-hydroxypyrid-4-one, CP94, relates to differing metabolism of the iron chelating site
66. Urinary metabolic profiles in human and rat of 1,2-dimethyl and 1,2-diethyl-substituted 3-hydroxypyrid-4-ones
67. Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one
68. Comparison of the pharmacokinetics of 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in healthy volunteers, with and without co-administration of ferrous sulfate, to thalassemia patients
69. 1,2-Dimethyl-3-hydroxyprid-4-one: An orally active chelator for treatment of iron overload
70. Agranulocyosis and thrombocytopaenia in a patient with Blackfan-Diamond anaemia during oral iron chelator trial
71. Long term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1): Clinical trial observations
72. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyridin-4-one (L1) in thalassemia major
73. Iron-chelation therapy with oral deferiprone in patients with thalassemia major
74. L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major
75. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial
76. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major
77. Final results of the randomized trial of deferiprone (L1) and deferoxamine (DFO)
78. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients
79. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients
80. Deferiprone: The long term cumulative experience
81. A multicenter safety trial of the oral iron chelator deferiprone
82. Safety profile of the oral iron chelator deferiprone: A multicentre study
83. Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone)
84. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1)
85. Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine
86. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone
87. Deferiprone: Its efficacy relative to that of desferal
88. Combined therapy with deferiprone and desferrioxamine
89. Iron chelation therapy: A better approach
90. Alternate use of deferiprone and desferrioxamine in primary school children with thalassaemia major
91. Sequential liver fibrosis grading during deferiprone treatment in patients with thalassemia major
92. The assessment of liver fibrosis in thalassemia major during chelation therapy
93. Iron chelation therapy with oral iron deferiprone in patients with thalassaemia
94. Liver assessment in a group of transfusion dependent patients treated with deferiprone and compared to a group of patients treated with desferrioxamine
95. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): A Dutch multicenter trial
96. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload
97. Oxygen sensing and signaling: Impact on the regulation of physiologically important genes
98. Deferiprone therapy in homozygous human beta-thalassemia removes erythrocyte membrane free iron and reduces KCl cotransport activity
99. Design of orally active iron chelators
100. Improved efficacy-toxicity ratios with oral iron chelators
101. Synthesis, physicochemical properties and biological evaluation of aromatic ester prodrugs of 1-(2′-hydroxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP102): Orally active iron chelators with clinical potential
102. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents
103. The release of iron and transferrin from the human melanoma cell
104. Ferric pyridoxal isonicotinoyl hydrazone can provide iron for heme synthesis in reticulocytes
105. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal
106. Pyridoxal complexes as potential chelating agents for oral therapy in transfusional iron overload
107. Pyridoxal isonicotinoyl hydrazone and analogues. Study of their stability in acidic, neutral and basic aqueous solutions by ultraviolet-visible spectrophotometry
108. Pyridoxal isonicotinoyl hydrazone: An effective iron chelation after oral administration
109. Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease
110. Iron chelators of the pyridoxal isonicotinoyl hydrazone class Part 2. Formation constants with iron (III) and iron (II)
111. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-Pyridylcarboxaldehyde isonicotinoyl hydrazone analogs
112. New multidentate ligands. VI. Chelating tendencies of N, N′-di(2-hydroxybenzoyl)ethylenediamine-N, N′-diacetic acid
113. Phenolic ethylenediamine derivatives: A study of orally effective iron chelators
114. Results from a phase I clinical trial of HBED
115. HBED the continuing development of a potential alternative to deferoxamine for iron-chelating therapy
116. Oral iron chelation: A potential role for HBED in combination therapy
117. IRC11, a new synthetic chelator with selective interaction with catabolic red blood cell iron. Evaluation in hypertransfused rats with hepatocellular and reticuloendothelial radioiron probes and in iron-loaded rat heart cells in culture
118. ICL670A: A new, potent, orally active iron chelator
119. ICL670A: A new synthetic oral chelator: Evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and RE iron stores and in iron-loaded rat heart cells in culture
120. CGP 72 670: A new, potent, orally active iron chelator
121. A novel oral iron chelator (ICL 670A): Update on a phase I single dose safety study
122. Cellular uptake and release of two contrasting iron chelators
123. Non-transferrin-bound iron (NTBI) in sera of thalassemic patients during oral chelation treatment
124. Deferiprone: How to make it work more widely, effectively and without adverse effect: An Indian study
125. Iron chelators: Mode of action of antimalarials
126. Design of orally active iron chelators
127. The development of iron chelating drugs
128. The hexadentate hydroxypyridinonate TREN-(Me-3,2-HOPO) is a more orally active iron chelator than its bidentate analogue
129. Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice